


FIDELIO-DKD

#AHA20



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with T2DM and CKD were randomized to either finerenone or placebo. Patients were followed for 2.6 years.



RESULTS

- Primary composite outcome (kidney failure, sustained decrease of 40% in eGFR from baseline, or death from renal causes) for finerenone vs. placebo: 17.8% vs. 21.1% (p = 0.0014)
 - Kidney failure: 7.3% vs. 8.3%, ESKD: 4.2% vs. 4.9%
- Secondary outcome for finerenone vs. placebo
 - CV death, MI, stroke, HHF: 13% vs. 14.8% (p = 0.03)
 - Hyperkalemia: 15.8% vs. 7.8%

CONCLUSIONS

- Results indicate that finerenone has salutary effects on CV and renal outcomes among patients with T2DM and CKD; risk of hyperkalemia was higher

Filippatos G, et al. *Circulation* 2020;Nov 16:[Epub]